| Literature DB >> 33594276 |
Michele Simonato1,2, Denes V Agoston3, Amy Brooks-Kayal4, Chris Dulla5, Brandy Fureman6, David C Henshall7,8, Asla Pitkänen9, William H Theodore10, Roy E Twyman11, Firas H Kobeissy12,13, Kevin K Wang12,14, Vicky Whittemore10, Karen S Wilcox15.
Abstract
Onset of many forms of epilepsy occurs after an initial epileptogenic insult or as a result of an identified genetic defect. Given that the precipitating insult is known, these epilepsies are, in principle, amenable to secondary prevention. However, development of preventive treatments is difficult because only a subset of individuals will develop epilepsy and we cannot currently predict which individuals are at the highest risk. Biomarkers that enable identification of these individuals would facilitate clinical trials of potential anti-epileptogenic treatments, but no such prognostic biomarkers currently exist. Several putative molecular, imaging, electroencephalographic and behavioural biomarkers of epileptogenesis have been identified, but clinical translation has been hampered by fragmented and poorly coordinated efforts, issues with inter-model reproducibility, study design and statistical approaches, and difficulties with validation in patients. These challenges demand a strategic roadmap to facilitate the identification, characterization and clinical validation of biomarkers for epileptogenesis. In this Review, we summarize the state of the art with respect to biomarker research in epileptogenesis and propose a five-phase roadmap, adapted from those developed for cancer and Alzheimer disease, that provides a conceptual structure for biomarker research.Entities:
Mesh：
Substances：
Year: 2021 PMID： 33594276 DOI： 10.1038/s41582-021-00461-4
Source DB: PubMed Journal: Nat Rev Neurol ISSN： 1759-4758 Impact factor: 42.937